Targeting neuropilin 1 as an antitumor strategy in lung cancer

Tse Ming Hong, Yuh Ling Chen, Yi Ying Wu, Ang Yuan, Yu Chih Chao, Yi Chuan Chung, Ming Heng Wu, Shuenn Chen Yang, Szu Hua Pan, Jin Yuan Shih, Wing Kai Chan, Pan Chyr Yang

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Purpose: Neuropilin 1 (NRP1) is a mediator of lung branching and angiogenesis in embryonic development and angiogenesis in cancer. The role of NRP1 in cancer progression is not fully elucidated. We investigated the role of NRP1 in cancer invasion and tumor angiogenesis, its signaling pathways, prognostic significance, and therapeutic implications. Experimental Design: Sixty patients with non-small cell lung cancer (NSCLC) were studied. NRP1 mRNA expression was measured using real-time quantitative reverse-transcription PCR. NRP1 and cancer cell invasion, angiogenesis, and signaling pathways were studied using NRP1 stimulation by vascular endothelial growth factor 165 (VEGF 165) and NRP1 inhibition by small interfering RNAs (siRNA), soluble NRP1 (sNRP1), and NRP1-inhibition peptides. The NRP1-inhibition peptides were identified using a phage display peptide library. Results: NSCLC patients with high expression of NRP1 had shorter disease-free (P = 0.0162) and overall survival (P = 0.0164; log-rank test). Multivariate analyses showed NRP1 is an independent prognostic factor in overall (HR, 2.37, 95% CI = 1.15 to 4.9, P = 0.0196) and disease-free survival [hazard ratio (HR), 2.38; 95% confidence interval (95% CI), 1.15-4.91; P = 0.0195] of NSCLC patients. Knockdown of NRP1 suppressed cancer cell migration, invasion, filopodia formation, tumorigenesis, angiogenesis, and in vivo metastasis. NRP1 signaling pathways involved VEGF receptor 2 and phosphoinositide-3-kinase (PI3K) and Akt activation. Two potent synthetic anti-NRP1 peptides, DG1 and DG2, which block NRP1 signaling pathways and suppress tumorigenesis, cancer invasion, and angiogenesis, were identified. Conclusions: NRP1 is a cancer invasion and angiogenesis enhancer. NRP1 expression is an independent predictor of cancer relapse and poor survival in NSCLC patients. NRP1 plays a critical role in tumorigenesis, cancer invasion, and angiogenesis through VEGF, PI3K, and Akt pathways. NRP1 may have potential as a new therapeutic target in NSCLC.

Original languageEnglish
Pages (from-to)4759-4768
Number of pages10
JournalClinical Cancer Research
Volume13
Issue number16
DOIs
Publication statusPublished - 2007 Aug 15

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Targeting neuropilin 1 as an antitumor strategy in lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Hong, T. M., Chen, Y. L., Wu, Y. Y., Yuan, A., Chao, Y. C., Chung, Y. C., Wu, M. H., Yang, S. C., Pan, S. H., Shih, J. Y., Chan, W. K., & Yang, P. C. (2007). Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clinical Cancer Research, 13(16), 4759-4768. https://doi.org/10.1158/1078-0432.CCR-07-0001